Rebus Holdings Inc (RBSH)

[Mrragu]

Phyton Biotech announced that it has achieved a major milestone in connection with the manufacture of thapsigargin, an inhibitor derived from the Thapsia plant that is the active agent for the investigational prodrug mipsagargin.

This notice was from a while back and the patent to produce the thapsigargin is still not issued by the US patent office.

Phyton produces drugs from plants. It's blockbuster drug is Paclitaxel (TAXOL). It's patent on TAXOL enabled the drug to be a world wide treatment for Breast Cancer.

Opinions and rumors feel that once the patent is granted for the commercialized production of thagsagargin there would be ample product to make sufficient doses of mipsagarin to proceed with PH III.

It's the opinion and rumor that no PH III clinical trial can proceed until Phyton gets the patent for the production of thapsagargin issued. The opinion is that no pharma company would spend the money on the drug until it was assured there would be enough product in the pipeline to sufficiently make the doses needed.